Pembina Pipeline announced today that its Board of Directors declared a common share cash dividend for March 2017 of $0.16 per share to be paid, subject to applicable law, on April 15, 2017 to shareholders of record on March 25, 2017. The Children’s Place, the largest pure-play children’s specialty apparel retailer in North America, today announced that its Board of Directors has approved a new $250 million share repurchase program and has increased the Company’s quarterly dividend to $0.40 per share from $0.20 per share.
Category: Amgen
Amgen beats Street 4Q forecasts
The Thousand Oaks, California-based company said it had net income of $2.59 per share. Earnings, adjusted for non-recurring costs, came to $2.89 per share.
Amgen Cholesterol-Lowering Drug Repatha Cuts Heart-Related Adverse Events in Big Study
The outcome of the so-called ‘FOURIER’ trial is extremely important for Amgen because the data will be used to lobby insurance companies to reimburse for Repatha. Amgen said Wednesday that its cholesterol-lowering drug Repatha achieved all efficacy endpoints in a closely watched clinical trial by reducing the risk of adverse cardiovascular events, including death.
U.S. Stocks Waver Between Modest Gains And Losses After Jobs Report
U.S. stocks wavered between modest gains and losses after Friday’s open following an upbeat report on U.S. jobs growth in December. The Dow Jones Industrial Average was flat at 19,903.
Amgen Wins Ban on Sanofi’s Praluent Cholesterol Drug Sales
Amgen Inc. won a court ruling blocking rivals Sanofi and Regeneron Pharmaceuticals Inc. from selling their cholesterol-lowering drug Praluent in the U.S. because it infringes Amgen’s patents covering a rival treatment. U.S. District Judge Sue Robinson in Delaware ordered Sanofi and Regeneron Thursday to halt Praluent sales for 12 years because the drug infringes patents on Amgen’s Repatha medication.
Amgen Wins Ban on Sanofi’s Praluent Cholesterol Drug Sales
Amgen Inc. won a court ruling blocking rivals Sanofi and Regeneron Pharmaceuticals Inc. from selling their cholesterol-lowering drug Praluent in the U.S. because it infringes Amgen’s patents covering a rival treatment. U.S. District Judge Sue Robinson in Delaware ordered Sanofi and Regeneron to halt Praluent sales for 12 years because the drug infringes patents on Amgen’s Repatha medication.